Background The use of direct oral anticoagulants (DOACs) in obese patients is uncertain. It
is unclear if body mass index (BMI) affects the safety and efficacy of DOACs for the primary …

Introduction Apixaban, a direct factor Xa inhibitor, has been shown to be at least as safe and
probably more effective than dalteparin for the treatment of cancer‐associated thrombosis …

Background: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce
the risk of venous thromboembolism (VTE) compared with placebo for the primary …

Introduction: Apixaban 2.5 mg twice daily has been shown to significantly reduce the risk of
venous thromboembolism (VTE) compared to placebo for the primary thromboprophylaxis of …

Venous thromboembolism (VTE) is a common complication in ambulatory cancer patients
receiving chemotherapy. Current clinical guidelines recommend against the use of routine …

Dear Editor, We appreciated reading the original article titled “Low dose apixaban as
secondary prophylaxis of venous thromboembolism in cancer patients–30 months follow up” …

Cancer is a leading cause of venous thromboembolism (VTE), which contributes to
significant morbidity and mortality in these patients. Increased thrombotic risk in cancer …

Background Thromboprophylaxis for ambulatory patients with cancer is effective, although
uncertainties remain on who should be targeted. Using D‐dimer values from individuals …

Patients with active cancer have a heightened risk of venous thromboembolism (VTE). This
risk is further increased by the initiation of chemotherapy. Although previous studies have …

Background The risk of venous thromboembolism (VTE) is increased in patients with active
cancer and the risk is highest in those with metastatic disease. The risks and benefits of …